FDA approves new shot for two nerve and muscle conditions.

The FDA has approved a new medicine called Vyvgart Hytrulo. It is a shot given under the skin once a week. This drug treats two conditions: generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Both are long term nerve and muscle disorders that can cause weakness. Vyvgart Hytrulo works by blocking a protein that affects the immune system. It is for adults with gMG who have a certain antibody (anti AChR positive) and for adults with CIDP. This approval is important because it offers a shot that can be given at home. Before this, some patients had to go to a clinic for IV treatments. The shot may be more convenient for some people. However, the drug can lower IgG levels, which are part of the immune system. Because of this, doctors should check if patients need certain vaccines before starting treatment. If you have gMG or CIDP, talk to your doctor to see if Vyvgart Hytrulo might be right for you. This is a new option, not a cure. Your doctor can help you understand the benefits and risks.